SCHEMBL18409223

SCHEMBL18409223

C=CN/N=C\N(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19773657 0.81
SCHEMBL18723464 0.75
SCHEMBL21508639 0.74
SCHEMBL18723423 0.72
SCHEMBL14114721 0.72
SCHEMBL10326155 0.67
SCHEMBL903274 0.67
SCHEMBL14607883 0.67
SCHEMBL21508644 0.66
SCHEMBL20643284 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024044570-A1 COMPOUNDS AND METHODS FOR MODULATING HER2 IAMBIC THERAPEUTICS, INC. (US) 2024-02-29 WO disclosed
EP-3397629-B1 METALLOENZYME INHIBITOR COMPOUNDS NQP 1598 LTD (KY) 2023-04-19 EP disclosed
US-10000496-B2 Compositions useful for treating disorders related to kit and PDGFR BLUEPRINT MEDICINES CORPORATION (US) 2018-06-19 US disclosed
EP-3269713-A1 PIPERIDINE DERIVATIVES AS NK1 ANTAGONISTS OPKO Health, Inc. (US) 2018-01-17 EP disclosed
EP-2522664-B1 Piperidine derivatives as NK1 antagonists OPKO HEALTH INC (US) 2017-04-12 EP disclosed
US-20170022206-A1 COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT AND PDFGR BLUEPRINT MEDICINES CORPORATION 2017-01-26 US disclosed